Researchers have found blood proteins that cause migraines and have a shared link with Alzheimer’s disease that could potentially be prevented by repurposing existing therapeutics.
List view / Grid view
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
10 June 2016 | By Victoria White, Digital Content Producer
The grant will be used to build a registry that will contain clinical data to advance the research and discovery of new treatments for migraine...
12 January 2016 | By Victoria White
Cortical spreading depressions (CSDs) are believed to be responsible for the aura, or visual disturbance, that frequently precedes some migraines, and have been a significant target for pharmaceutical development...
25 November 2015 | By Victoria White
The companies have entered an agreement to discover and develop novel, small-molecule CGRP antagonists for the treatment of migraine...
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...